COMMUNIQUÉS West-GlobeNewswire

Amarin Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for Vascepa® (icosapent ethyl) to Reduce the Risk of Major Adverse Cardiovascular Events Based on Landmark REDUCE-IT™ Cardiovascular Outcomes Study
28/03/2019
BEDMINSTER, N.J., and DUBLIN, Ireland, March 28, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that, as planned, it [...]
Molecular Templates, Inc. Reports Fourth Quarter 2018 Financial Results
28/03/2019
AUSTIN, Texas, March 28, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular” or “Molecular Templates”), a clinical-stage oncology company focused on the discovery and development of the company [...]
Microbix Announces Annual Meeting Voting Results
28/03/2019
TORONTO, March 28, 2019 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, “ Microbix ” or the “ Company ”), an innovator of biological products and technologies, announces the voting results from the Annual [...]
Neurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinson’s Disease in the Annals of Neurology
28/03/2019
SAN DIEGO and CAMBRIDGE, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Voyager Therapeutics, Inc. (NASDAQ: VYGR) today announced the publication of interim results from the [...]
Equillium to Present at H.C. Wainwright Global Life Sciences Conference
28/03/2019
LA JOLLA, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that Dan Bradbury, Equillium’s [...]
Kezar Life Sciences Announces Presentations at Upcoming Scientific Conferences
28/03/2019
SOUTH SAN FRANCISCO, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat [...]
Forty Seven Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights
28/03/2019
-- Updated Data from Phase 1b/2 Trial of 5F9 in Combination with Rituximab in Relapsed/Refractory Non-Hodgkin’s Lymphoma (r/r NHL) Expected in Second Quarter of 2019 – -- Updated Data from Phase 1b Trial of 5F9 as a [...]
Dynavax Announces European Medicines Agency Accepts Marketing Authorization Application for HEPLISAV-B® for Prevention of Hepatitis B in Adults
28/03/2019
BERKELEY, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology [...]
SpineEX Begins Commercial Launch of its Sagittae Lateral Lumbar Interbody Fusion (LLIF) Device
28/03/2019
FREMONT, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- SpineEX Inc, a medical device company focused on the design, development and marketing of products for spine disorders, has officially begun the commercial launch of [...]
Achaogen Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
28/03/2019
-- ZEMDRI’s once-daily 30-minute infusion facilitating usage in the outpatient setting -- -- Company’s recent restructuring aimed at conserving capital to continue assessment of strategic alternatives -- -- Conference [...]
Capricor Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
28/03/2019
Plan to Report Interim Data from HOPE-2 Clinical Trial in Early Q3 To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, March 28, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a [...]
Gritstone Oncology Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights
28/03/2019
EMERYVILLE, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer [...]
Visual Snow Initiative to present a Váró-abstract brain sculpture to MIT Neuroscientist Ed Boyden for his support to advance a ‘Visual Snow’ cure
28/03/2019
Attn.: Boston Assignment/Photo Editors, Art Editors, Healthcare Editors, Tech Editors Media Advisory: April 3 - Photo & Interview Opportunity Who: Dr. Ed Boyden , Assoc. Professor, Biological Engineering and Brain [...]
B. Braun Offering Plenamine™ 15% Amino Acids Injection in Flexible Containers
28/03/2019
BETHLEHEM, Pa., March 28, 2019 (GLOBE NEWSWIRE) -- B. Braun Medical Inc., a leader in parenteral nutrition, now offers Plenamine 15% Amino Acids Injection in 1-liter Pharmacy Bulk Package (PBP) flexible containers. With [...]
Deinove 2018 Annual Results: a year of significant progress
28/03/2019
Finalization of the acquisition of DNV3837, a promising antibiotic for treating severe gastrointestinal infections caused by Clostridium difficile , expected to begin Phase II in mid-2019 Successful start of the AGIR [...]
Assertio Therapeutics Announces Favorable NUCYNTA® Patent Ruling
28/03/2019
LAKE FOREST, Ill., March 28, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that the United States Court of Appeals for the Federal Circuit has ruled in favor of Assertio with [...]
Explanations Regarding Cancellation of Decision to Convene Extraordinary General Meeting scheduled for April 1st, 2019
28/03/2019
Reacting to the request by AS Nasdaq Riga received on March 28, 2019, regarding the cancellation of decision to convene the Extraordinary General Meeting scheduled for April 1 st , AS Olainfarm provides the following [...]
Emerald Health Therapeutics Announces At-the-Market Equity Program
28/03/2019
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, March 28, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald” or the “ [...]
OSE Immunotherapeutics Reports 2018 Financial Results and Business Update
28/03/2019
Four differentiated therapeutic programs progressing through clinical studies in immuno-oncology and autoimmune diseases OSE’s partnership business model based on innovative products; Multiple validating partnering [...]

Pages